Caplin Point Laboratories Ltd
Tue 6/05/2025,15:43:57 | NSE : CAPLIPOINT
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 1899.50
Previous Close
₹ 1906.40
Volume
90326
Mkt Cap ( Rs. Cr)
₹14082.69
High
₹ 1902.40
Low
₹ 1830.10
52 Week High
₹ 2641.00
52 Week Low
₹ 1225.00
Book Value Per Share
₹ 334.49
Dividend Yield
0.26
Face Value
₹ 2.00
What’s Your Call?
Collective community sentiment on Caplin Point Laboratories Ltd
Your Vote -
Buy
76.21%
Hold
4.37%
Sell
19.42%
76.21%
206 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
1852.70
462
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
462
Option Chain
Analyzes market sentiment, predicts Caplin Point Laboratories Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers caplin point laboratories ltd stock attention, sentiment.
-
Caplin Point Lab - Press Release
-
Caplin Point Lab - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Caplin Point Lab - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Caplin Point Lab - Cessation
-
Caplin Point Lab - Announcement under Regulation 30 (LODR)-Cessation
-
Caplin Point Lab has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025
-
Caplin Point Lab - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Caplin Point Lab - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Caplin Point Lab - General Updates
-
Caplin Point Lab - Announcement under Regulation 30 (LODR)-Acquisition
-
Caplin Point Lab - Action(s) taken or orders passed
-
Caplin Point Lab - Cautionary Letter From NSE And BSE On March 28, 2025
-
Caplin Point Lab - Trading Window-XBRL
-
Caplin Point Lab - Trading Window
-
Caplin Point Lab - Press Release
-
Caplin Point Lab - Analysts/Institutional Investor Meet/Con. Call Updates
-
Caplin Point Lab - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
-
Caplin Point Lab - Copy of Newspaper Publication
-
Caplin Point Lab - Analysts/Institutional Investor Meet/Con. Call Updates
-
Caplin Point Lab - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
-
Caplin Point Lab - Integrated Filing- Financial
-
Caplin Point Lab - Integrated Filing (Financial)
-
Caplin Point Lab - Financial Result Updates
-
Caplin Point Lab Q3 net profit up 34.73% at Rs 74.71 cr
-
Caplin Point Lab - Outcome of Board Meeting
-
Caplin Point Lab - Board Meeting Outcome for Board Meeting Outcome Of The Financial Results For The Quarter Ended December 31
-
Caplin Point Lab - Financial Results For The Quarter Ended December 31, 2024
-
Caplin Point arm gets USFDA approval for Phytonadione Injectable Emulsion
-
Caplin Point Laboratories
-
Caplin Steriles gets USFDA approval for Procainamide Hydrochloride Injection
-
Caplin Point arm gets USFDA nod for Levetiracetam
-
Caplin Point Laboratories
-
Caplin Point Laboratories
-
Stock Update: Caplin Point
-
Caplin Point Q1FY25 results
-
Caplin Point Laboratories Ltd
-
Caplin Steriles gets USFDA nod for Ephedrine Sulfate Injection USP
-
Caplin Point arm gets USFDA nod for ANDA
-
Caplin Points gets USFDA approval for ANDA Ofloxacin ophthalmic solution
-
Stock Update: Caplin Point Laboratories
-
Caplin Point Laboratories
-
Caplin Point arm gets final USFDA nod for ANDA Ofloxacin Otic Solution
-
View Point update – Caplin Point Q2FY24 results review
-
Caplin Steriles receives EIR from USFDA
-
Caplin Point Labs
-
Caplin Point Laboratories
-
Caplin Point Laboratories
-
Caplin Steriles gets USFDA ANDA nod for Cisatracurium Besylate Injection
-
Caplin Point Laboratories
-
Caplin Steriles gets USFDA nod for Ketorolac Tromethamine injection
-
Caplin Point Labs
-
Caplin Point gets USFDA nod for Thiamine Hydrochloride Injection
-
Caplin Point Labs
-
Caplin Steriles gets USFDA nod for Rocuronium Bromide Injection
-
Caplin Point Laboratories
-
Viewpoint - Caplin Point Laboratories
-
Caplin Point Labs Q3FY22 results
-
Caplin Point Q3 net profit surges by 13.6% YoY
-
Viewpoint – Caplin Point Laboratories
-
Viewpoint – Caplin Point Laboratories
-
Caplin Point's cro amaris clinical completes USFDA audit with nil observations
-
Caplin Point Laboratories
-
Caplin Point Lab gets USFDA nod for its Labetalol Hydrochloride Injection
-
Caplin Point Laboratories
-
Caplin Steriles receives nod from Brazil's Anvisa
-
Caplin Point Laboratories (Viewpoint) : Result Update
-
Caplin Point Laboratories Q1FY22 results
-
Caplin Point Laboratories
-
Caplin Steriles gets USFDA approval for Sumatriptan Injection
-
Caplin Point Laboratories – Viewpoint
-
Caplin Steriles gets USFDA approval for Prochlorperazine Edisylate Injectionn FY 2003-04
-
Caplin Point surges on USFDA nod
-
Caplin Steriles gets USFDA nod for Argatroban Injection
-
Caplin Steriles enters into a strategic partnership with Jamp Pharma group for Canada
-
Caplin Point gets USFDA nod
-
Caplin Steriles to license five of its injectable ANDAs to Xellia Pharmaceuticals
-
Caplin Steriles gets USFDA nod for Phenylephrine Hydrochloride Injection USP
-
Caplin Point gets USFDA nod for Ropivacaine Hydrochloride Injection
-
Caplin Steriles gets USFDA approval for Verapamil Hydrochloride Injection USP
-
Caplin Steriles gets USFDA approval for Sodiume Nitroprusside Injections
-
Caplin Point gets USFDA inspection report for injectable unit
-
Caplin Steriles gets USFDA approval for Tranexamic Acid Injection
-
Caplin Point gets Colombia approval for Sterile Injectables
-
Caplin Point arm inks pact with Baxter Healthcare Corporation
-
Caplin Points up after USFDA inspection
Key fundamentals
Evaluate the intrinsic value of Caplin Point Laboratories Ltd stock
Name | March-24 | March-23 | March-22 | March-21 | March-20 |
---|---|---|---|---|---|
Assets | 1390.15 | 1139.91 | 930.65 | 758.6853 | 600.1883 |
Liabilities | 1390.15 | 1139.91 | 930.65 | 758.6853 | 600.1883 |
Equity | 15.19 | 15.18 | 15.16 | 15.1286 | 15.1286 |
Gross Profit | 287.08 | 219.92 | 219.62 | 213.9248 | 206.9924 |
Net Profit | 283.71 | 234.26 | 187.87 | 156.2198 | 197.6385 |
Cash From Operating Activities | 104.21 | 157.1 | 230.97 | 294.6452 | 87.0055 |
NPM(%) | 45.38 | 44.31 | 35.57 | 32.36 | 37.44 |
Revenue | 625.09 | 528.61 | 528.06 | 482.6796 | 527.8253 |
Expenses | 338.01 | 308.69 | 308.44 | 268.7548 | 320.8329 |
ROE(%) | 11.15 | 9.21 | 7.38 | 6.14 | 7.77 |
Corporate Action
XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
---|---|---|---|---|
23 Sep 2024 | 2.5 | 125 | 0.27 | 1580.8 |
31 May 2024 | 2.5 | 125 | 0.27 | 1363.8 |
14 Sep 2023 | 2.5 | 125 | 0.27 | 896 |
21 Sep 2022 | 2 | 100 | 0.27 | 820.15 |
23 May 2022 | 2 | 100 | 0.27 | 663.3 |
20 Sep 2021 | 1.5 | 75 | 0.27 | 913.6 |
18 May 2021 | 1.5 | 75 | 0.27 | 560.3 |
21 Sep 2020 | 0.4 | 20 | 0.27 | 368.75 |
12 Mar 2020 | 2.1 | 105 | 0.27 | 299.1 |
04 Sep 2019 | 2.2 | 110 | 0.27 | 397.65 |
18 Sep 2018 | 2 | 100 | 0.27 | 595.25 |
07 Sep 2017 | 1.5 | 75 | 0.27 | 470.8 |
01 Sep 2016 | 3.5 | 35 | 0.27 | 998.85 |
15 Feb 2016 | 2.5 | 25 | 0.27 | 1206.8 |
29 Oct 2015 | 5 | 50 | 0.27 | 1364.4 |
11 Dec 2014 | 4 | 40 | 0.27 | 420.2 |
Peers
Other companies within the same industry or sector that are comparable to Caplin Point Laboratories Ltd
Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
---|---|---|---|---|---|---|
Albert David Ltd | 814.90 | -3.22 | 11.50 | 1059.34 | 1321.50 | 1.41 |
Lotus Eye Hospital and Institute Ltd | 74.33 | -1.01 | 309.71 | 3860.11 | 14.01 | 0.67 |
Vaishali Pharma Ltd | 11.94 | -1.24 | 398.00 | 1989.65 | 2.76 | 0.00 |
Astec Lifesciences Ltd | 666.80 | -0.94 | 0.00 | 3639.75 | -687.11 | 0.00 |
Company Info
The Company was incorporated on 16th April, 1990 under the Act as a Private Limited Company under the name of CAPLIN POINT LABORATORIES PRIVATE LIMITED. The name of the Company was changed to CAPLIN POINT LABORATORIES LIMITED effective 23rd April 1993. The Company has adopted a new set of Articles on 12th March, 1993 as applicable to public limited companies. The Company was incorporated as an extension of a pharmaceutical manufacturing unit started by M/s Triwin Pharmaceuticals, the first pharmaceutical venture started by Mr. P C Partheeban (presently the Managing Director), Mr. T Palanisamy and Mr. S Karunakaran in the year 1987 as a partnership firm. In the year 1990, the Company was incorporated by the partners of the aforesaid firm alongwith Mr. B A Ahmed. Soon thereafter, Mr. S Jayaraman joined the Board to take charge of production. Recently, the Board has been recast with all Directors except Mr.P.C.Partheeban making room for broadbasing the Board. The resigning Directors have taken positions as Senior level Managers in the Company. M/s Triwin Pharmaceuticals was engaged in the business of manufacture of Tablets, Liquid orals and Capsules (Non-Antibiotic) and Import Sales of family planning and certain life saving drugs. The said firm also started the Export of manufactured formulations in the year 1992-93. Even after the incorporation of the Company, the firm continued its manufacturing, sales and export of Tablets, Liquid orals and Capsules (Non-Antibiotic) and business of import sales while the Company started the manufacture of Ointments, Oral Powders and Capsules (Antibiotic). The said firm has since been taken over by the Company with effect from 1st September, 1993 with the objective of consolidation of the business of the Company into a single larger entity for setting up the Project envisaged. All the assets and liabilities of the firm were taken over at book values as at 31st August 1993. The Company's turnover in future shall comprise of the sales generated from the manufacturing faculties of the erstwhile firm also. Salient terms of the takeover Agreement executed by the Company with M/s. Triwin Pharmacuticals ('Triwin') are as follows. a. Transfer and vesting of assets and liabilities of Triwin in the Company All the assets and liabilities of Triwin including its factory located at No. 44, Kamakoti Nagar Annexe,Valasaravakkam, Madras 600 087, on going business basis are transferred at book values as on 31st August 1993. b. Net consideration for the transfer of assets and liabilities Consideration payable by the Company shall be the net worth of Triwin (excluding good will) estimated at Rs.31,62,000 on the basis of its audited accounts as at 31st August 1993. c. Continuance of Business In the post-transfer stage, the Company to continue to do the business then carried on by Triwin (including the manufacturing operation) and Triwin shall suspend all the production/sales activities hitherto carried on by them. d. Discharge of Purchase consideration The Company to issue at par its Shares credited as fully paid-up to the partners of Triwin for an aggregate nominal value of Rs. 31,62,000 (Rupees Thirty One lacs Sixty Two Thousand only) in the proportion of amounts lying to the credit of the respective capital/current accounts as on 31st August 1993. 2010 -Caplin Point Laboratories Ltd has recommended a final dividend of Re. 1/- per share (10%) 2011 -Caplin Point Laboratories Ltd has Recommended a final Dividend of Re. 1.50 per share (15%) -Mr. Vivek Siddharth has been appointed as the Chief Operating Officer of the Company 2012 -Caplin Point Laboratories Ltd has recommended dividend a final dividend of Rs. 2/- per share (20%) -Mr. D. P. Mishra has been appointed as a Whole Time Director of the Company 2013 -Mr. Mohanraj has been appointed as the Vice President - Finance and Company Secretary of the company. 2014 -Caplin has commenced its additional line of Production in the area of Suppositories which is unique in its feature which very few Pharma Companies have. -Caplin Point Lab gets listing on Forbes Asia and rsquo;s ‘200 Best Billion and rsquo; 2014. 2015 -Caplin Point Lab - Caplin Point gets EU GMP approval for Sterile Injectable Site -Caplin Point Lab - Caplin Point gets Brazil's Anvisa approval for Sterile Injectable Site 2016 -Caplin Point Lab - US FDA inspection completed at Caplin Point's Injectable site. 2017 -Caplin Point Laboratories received approval from the U.S. Food and Drug Administration (USFDA) of its Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection 30mg/mL, a product developed for Cycle Pharmaceuticals. -Caplin Point gets USFDA nod for Ketorolac Tromethamine Injection. 2018 -USFDA completes inspection at Caplin Point Lab's sterile injectable facility in Tamil Nadu. 2019 -Caplin Point Laboratories partners with Baxter Corporation for injectable portfolio. -USFDA completes inspection at Caplin Steriles Injectable site. -Caplin Steriles gets USFDA nod for hemorrhage prevention drug. -Caplin Point Labs gets EIR from USFDA for injectable facility. 2020 -Caplin Point Laboratories Chairman C C Paarthipan said the company has partnered with Xellia which has a long standing track record of commercial success in the US for injectable products. -Caplin Point Laboratories received the final approval from the US drug regulator for its Abbreviated New Drug Application (ANDA) Phenylephrine Hydrochloride injection. -Caplin Point Laboratories Ltd -Caplin Steriles Gets USFDA Approval For Verapamil Hydrochloride Injection USP 2021 -Caplin Point arm inks strategic partnership with Canada's JAMP Pharma Group. -Caplin Point Laboratories arm gets USFDA nod for Neostigmine Methylsulfate Injection. 2023 - Lifetime Achievement Award 2023-Business - Forbes Asia Best Under Billion Award 2023
The Company was incorporated on 16th April, 1990 under the Act as a Private Limited Company under the name of CAPLIN POINT LABORATORIES PRIVATE LIMITED. The name of the Company was changed to CAPLIN POINT LABORATORIES LIMITED effective 23rd April 1993. The Company has adopted a new set of Articles on 12th March, 1993 as applicable to public limited companies. The Company was incorporated as an extension of a pharmaceutical manufacturing unit started by M/s Triwin Pharmaceuticals, the first pharmaceutical venture started by Mr. P C Partheeban (presently the Managing Director), Mr. T Palanisamy and Mr. S Karunakaran in the year 1987 as a partnership firm. In the year 1990, the Company was incorporated by the partners of the aforesaid firm alongwith Mr. B A Ahmed. Soon thereafter, Mr. S Jayaraman joined the Board to take charge of production. Recently, the Board has been recast with all Directors except Mr.P.C.Partheeban making room for broadbasing the Board. The resigning Directors have taken positions as Senior level Managers in the Company. M/s Triwin Pharmaceuticals was engaged in the business of manufacture of Tablets, Liquid orals and Capsules (Non-Antibiotic) and Import Sales of family planning and certain life saving drugs. The said firm also started the Export of manufactured formulations in the year 1992-93. Even after the incorporation of the Company, the firm continued its manufacturing, sales and export of Tablets, Liquid orals and Capsules (Non-Antibiotic) and business of import sales while the Company started the manufacture of Ointments, Oral Powders and Capsules (Antibiotic). The said firm has since been taken over by the Company with effect from 1st September, 1993 with the objective of consolidation of the business of the Company into a single larger entity for setting up the Project envisaged. All the assets and liabilities of the firm were taken over at book values as at 31st August 1993. The Company's turnover in future shall comprise of the sales generated from the manufacturing faculties of the erstwhile firm also. Salient terms of the takeover Agreement executed by the Company with M/s. Triwin Pharmacuticals ('Triwin') are as follows. a. Transfer and vesting of assets and liabilities of Triwin in the Company All the assets and liabilities of Triwin including its factory located at No. 44, Kamakoti Nagar Annexe,Valasaravakkam, Madras 600 087, on going business basis are transferred at book values as on 31st August 1993. b. Net consideration for the transfer of assets and liabilities Consideration payable by the Company shall be the net worth of Triwin (excluding good will) estimated at Rs.31,62,000 on the basis of its audited accounts as at 31st August 1993. c. Continuance of Business In the post-transfer stage, the Company to continue to do the business then carried on by Triwin (including the manufacturing operation) and Triwin shall suspend all the production/sales activities hitherto carried on by them. d. Discharge of Purchase consideration The Company to issue at par its Shares credited as fully paid-up to the partners of Triwin for an aggregate nominal value of Rs. 31,62,000 (Rupees Thirty One lacs Sixty Two Thousand only) in the proportion of amounts lying to the credit of the respective capital/current accounts as on 31st August 1993. 2010 -Caplin Point Laboratories Ltd has recommended a final dividend of Re. 1/- per share (10%) 2011 -Caplin Point Laboratories Ltd has Recommended a final Dividend of Re. 1.50 per share (15%) -Mr. Vivek Siddharth has been appointed as the Chief Operating Officer of the Company 2012 -Caplin Point Laboratories Ltd has recommended dividend a final dividend of Rs. 2/- per share (20%) -Mr. D. P. Mishra has been appointed as a Whole Time Director of the Company 2013 -Mr. Mohanraj has been appointed as the Vice President - Finance and Company Secretary of the company. 2014 -Caplin has commenced its additional line of Production in the area of Suppositories which is unique in its feature which very few Pharma Companies have. -Caplin Point Lab gets listing on Forbes Asia and rsquo;s ‘200 Best Billion and rsquo; 2014. 2015 -Caplin Point Lab - Caplin Point gets EU GMP approval for Sterile Injectable Site -Caplin Point Lab - Caplin Point gets Brazil's Anvisa approval for Sterile Injectable Site 2016 -Caplin Point Lab - US FDA inspection completed at Caplin Point's Injectable site. 2017 -Caplin Point Laboratories received approval from the U.S. Food and Drug Administration (USFDA) of its Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection 30mg/mL, a product developed for Cycle Pharmaceuticals. -Caplin Point gets USFDA nod for Ketorolac Tromethamine Injection. 2018 -USFDA completes inspection at Caplin Point Lab's sterile injectable facility in Tamil Nadu. 2019 -Caplin Point Laboratories partners with Baxter Corporation for injectable portfolio. -USFDA completes inspection at Caplin Steriles Injectable site. -Caplin Steriles gets USFDA nod for hemorrhage prevention drug. -Caplin Point Labs gets EIR from USFDA for injectable facility. 2020 -Caplin Point Laboratories Chairman C C Paarthipan said the company has partnered with Xellia which has a long standing track record of commercial success in the US for injectable products. -Caplin Point Laboratories received the final approval from the US drug regulator for its Abbreviated New Drug Application (ANDA) Phenylephrine Hydrochloride injection. -Caplin Point Laboratories Ltd -Caplin Steriles Gets USFDA Approval For Verapamil Hydrochloride Injection USP 2021 -Caplin Point arm inks strategic partnership with Canada's JAMP Pharma Group. -Caplin Point Laboratories arm gets USFDA nod for Neostigmine Methylsulfate Injection. 2023 - Lifetime Achievement Award 2023-Business - Forbes Asia Best Under Billion Award 2023
Read More
Parent Organisation
Caplin Point Laboratories Ltd.
Founded
16/04/1990
Managing Director
Dr.Sridhar Ganesan
NSE Symbol
CAPLIPOINTEQ
FAQ
The current price of Caplin Point Laboratories Ltd is ₹ 1852.70.
The 52-week high for Caplin Point Laboratories Ltd is ₹ 1902.40 and the 52-week low is ₹ 1830.10.
The market capitalization of Caplin Point Laboratories Ltd is currently ₹ 14082.69. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Caplin Point Laboratories Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Caplin Point Laboratories Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Caplin Point Laboratories Ltd shares.
The CEO of Caplin Point Laboratories Ltd is Dr.Sridhar Ganesan, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.